Nu-Med Grupa
Specialized network for oncological diagnostics and cancer treatment.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Debt | |
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 1402646 % | 5 % | 13 % | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 177344 % | 3 % | 5 % | 15 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1704 %) | (33 %) | (39 %) | (30 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Nu-Med Grupa is a Polish operator of specialized oncological hospitals and diagnostic centers, established in 2012. The company provides comprehensive cancer care, including radiotherapy, chemotherapy, brachytherapy, and advanced diagnostic imaging services such as MRI, CT, and PET-CT. It also operates oncological and hematological clinics. The company's business model is centered on providing services contracted with the Polish National Health Fund (NFZ), making treatments free for patients, although commercial services are also available.
The company's history began with an investment from Enterprise Investors (EI) in a radiotherapy center in Katowice in 2012, followed by the acquisition of a stake in a facility in Elbląg in 2013, which were then merged under the Nu-Med brand. Subsequently, the group expanded by opening new treatment centers in Tomaszów Mazowiecki (2015) and Zamość (2016), strategically located in underserved regions of Poland. By 2023, the group was treating nearly 10,000 patients annually across its facilities. In August 2024, it was announced that Nu-Med Grupa would be acquired by Affidea, a major pan-European provider of healthcare services, a move intended to enhance access to high-quality cancer care in Poland. Now part of the Affidea group, Nu-Med continues to collaborate closely with public hospitals.
Nu-Med utilizes modern medical technologies, including linear accelerators with Image-Guided RadioTherapy systems, and employs techniques like stereotactic radiotherapy to ensure high precision in treatments. A key aspect of its service is a patient-centric approach, which includes patient coordinators to guide individuals through the treatment process and a holistic model that incorporates psychological support, physiotherapy, and dietary advice. The company is also active in promoting public health awareness through cancer prevention workshops and screening events. It established the NU-MED Foundation in 2017 to support patients and their families.
Keywords: oncology, radiotherapy, chemotherapy, cancer treatment, diagnostic imaging, brachytherapy, Polish healthcare, oncological hospitals, PET-CT, National Health Fund, cancer care, hematology, medical diagnostics, Affidea, Enterprise Investors, lean management healthcare, patient coordinators, clinical trials, surgical oncology, cancer prevention